SE457800B - Plasminogenaktivatorderivat - Google Patents

Plasminogenaktivatorderivat

Info

Publication number
SE457800B
SE457800B SE8206173A SE8206173A SE457800B SE 457800 B SE457800 B SE 457800B SE 8206173 A SE8206173 A SE 8206173A SE 8206173 A SE8206173 A SE 8206173A SE 457800 B SE457800 B SE 457800B
Authority
SE
Sweden
Prior art keywords
urokinase
molecular weight
glycol
triazine
polyethylene glycol
Prior art date
Application number
SE8206173A
Other languages
English (en)
Swedish (sv)
Other versions
SE8206173L (sv
SE8206173D0 (sv
Inventor
Kimihiro Shimizu
Tsuguji Nakahara
Taketoshi Kinoshita
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of SE8206173D0 publication Critical patent/SE8206173D0/xx
Publication of SE8206173L publication Critical patent/SE8206173L/xx
Priority claimed from CA000443230A external-priority patent/CA1217718A/en
Publication of SE457800B publication Critical patent/SE457800B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8206173A 1981-10-30 1982-10-29 Plasminogenaktivatorderivat SE457800B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP56172908A JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
CA000443230A CA1217718A (en) 1981-10-30 1983-12-14 Plasminogen activator derivatives

Publications (3)

Publication Number Publication Date
SE8206173D0 SE8206173D0 (sv) 1982-10-29
SE8206173L SE8206173L (sv) 1983-05-01
SE457800B true SE457800B (sv) 1989-01-30

Family

ID=25670236

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8206173A SE457800B (sv) 1981-10-30 1982-10-29 Plasminogenaktivatorderivat

Country Status (9)

Country Link
US (1) US4495285A (OSRAM)
JP (1) JPS5896026A (OSRAM)
BR (1) BR8206347A (OSRAM)
CA (1) CA1203764A (OSRAM)
CH (1) CH658669A5 (OSRAM)
DE (1) DE3240174A1 (OSRAM)
FR (1) FR2515684B1 (OSRAM)
GB (1) GB2110219B (OSRAM)
SE (1) SE457800B (OSRAM)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0304311A1 (en) * 1987-08-21 1989-02-22 The Wellcome Foundation Limited Complex of polyethylene glycol and tissue plasminogen activator
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
IT1260468B (it) * 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
AU709054B2 (en) 1994-03-07 1999-08-19 Chiron Corporation Compositions for the inhibition of TNF formation and uses thereof
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
JP4193917B2 (ja) * 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー 架橋ポリマー組成物およびその使用方法
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
DE69731836T2 (de) * 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
US20020182172A1 (en) * 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP3372243A1 (en) 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CN1604787A (zh) * 2001-10-15 2005-04-06 希龙公司 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040219214A1 (en) * 2002-12-30 2004-11-04 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
SI1704166T1 (sl) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-scf specifiäśno monoklonsko protitelo in uporabe le-tega
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
NZ550964A (en) 2004-04-28 2011-05-27 Angiodevice Internat Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
WO2006034128A2 (en) 2004-09-17 2006-03-30 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
EP2305716B1 (en) 2004-11-30 2014-10-22 Celldex Therapeutics, Inc. Antibodies directed to gpnmb and uses thereof
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
US9580506B2 (en) * 2005-07-21 2017-02-28 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
ES2538036T3 (es) * 2005-07-28 2015-06-16 Novartis Ag Uso de anticuerpo a M-CSF
EP2311876A3 (en) * 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
WO2007068255A1 (en) 2005-12-15 2007-06-21 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
EP2407483A1 (en) 2006-04-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Methods of treating, diagnosing or detecting cancers
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
MX2009001341A (es) * 2006-08-04 2009-05-28 Novartis Ag Anticuerpos especificos de ephb3 y usos de los mismos.
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
US8377439B2 (en) 2006-12-07 2013-02-19 Novartis Ag Antagonist antibodies against EPHB3
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20130588A1 (es) * 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
EP2125898B1 (en) 2007-03-14 2013-05-15 Novartis AG Apcdd1 inhibitors for treating, diagnosing or detecting cancer
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
RU2010133892A (ru) 2008-01-24 2012-02-27 Ново Нордиск А/С (DK) Гуманизированные моноклональные антитела против человеческого nkg2a
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
US7833530B2 (en) 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
WO2010007463A1 (en) 2008-07-16 2010-01-21 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102203133B (zh) 2008-07-16 2015-01-07 生物医学研究学会 人巨细胞病毒中和抗体及其应用
NZ590890A (en) * 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010025555A1 (en) * 2008-09-08 2010-03-11 Ottawa Hospital Research Institute Periostin-induced pancreatic regeneration
MX2011003588A (es) 2008-10-13 2011-10-14 Inst Research In Biomedicine Anticuerpos neutralizadores del virus del dengue y uso de los mismos.
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2822610C (en) 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Use of anti-p-selectin antibodies
EA034031B1 (ru) 2011-01-06 2019-12-20 Бионор Иммуно Ас Димерный пептид для индуцирования иммунного ответа против hiv и его применение
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP4520771A3 (en) 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
KR102148982B1 (ko) 2011-06-03 2020-08-27 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US9498531B2 (en) 2012-03-20 2016-11-22 Humabs Biomed Sa Antibodies that neutralize RSV, MPV and PVM and uses thereof
BR112014030466A2 (pt) 2012-06-06 2017-09-12 Bionor Immuno As peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
JP6377635B2 (ja) 2013-01-10 2018-08-22 ゲンマブ ビー．ブイ． ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP6525951B2 (ja) 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アペリン融合タンパク質およびその使用
JP6463331B2 (ja) 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
ES2985805T3 (es) 2014-07-08 2024-11-07 Univ New York Ligandos de formación de imágenes de TAU y sus usos en el diagnóstico y el tratamiento de tauopatías
CA2952758A1 (en) 2014-07-11 2016-01-14 Genmab A/S Antibodies binding axl
CN106573154B (zh) 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
CN115607688A (zh) 2014-07-22 2023-01-17 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
MX2017001022A (es) 2014-07-24 2017-12-20 Genentech Inc Metodos para conjugar un agente a un resto tiol en una proteina que contiene al menos un enlace trisulfuro.
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016062722A1 (en) 2014-10-24 2016-04-28 Astrazeneca Ab Combination
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
SI3220947T1 (sl) 2014-11-18 2021-02-26 Humabs Biomed S.A. Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe
EP3237446B1 (en) 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
EP3292139B1 (en) 2015-05-05 2020-10-28 The Regents of The University of California H3.3 ctl peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
SMT202000359T1 (it) 2015-07-10 2020-09-10 Genmab As Coniugati anticorpo-farmaco specifici per axl per il trattamento del cancro
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
PT3334761T (pt) 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2017062966A1 (en) 2015-10-09 2017-04-13 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formyulamino) pyrimidine and uses thereof
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
KR20250130692A (ko) 2016-01-13 2025-09-02 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
BR112018004916A2 (pt) 2016-07-12 2018-12-11 H Lundbeck As anticorpos específicos para tau hiperfosforilada e métodos de uso dos mesmos
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
JP2019537621A (ja) 2016-10-04 2019-12-26 フェアバンクス ファーマシューティカルズ，インコーポレイテッド 抗ｆｓｔｌ３抗体およびその使用
CA3041988A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3548058B1 (en) 2016-12-05 2022-06-22 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
JP7144755B2 (ja) 2016-12-16 2022-09-30 ハー・ルンドベック・アクチエゼルスカベット 薬剤、使用および方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
CN110475546A (zh) 2017-02-06 2019-11-19 雷莫内克斯生物制药有限公司 生理活性物质载体
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
CA3063037A1 (en) 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
AU2019222705B2 (en) 2018-02-14 2025-10-09 Horizon Therapeutics Ireland Dac Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
EA202092593A1 (ru) 2018-04-30 2021-02-12 Такеда Фармасьютикал Компани Лимитед Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
US20210238229A1 (en) 2018-06-14 2021-08-05 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
CN113544148B (zh) 2018-12-19 2024-04-05 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
AU2020227824B2 (en) 2019-02-27 2025-07-10 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
JP7607579B2 (ja) 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法
WO2020210512A1 (en) 2019-04-09 2020-10-15 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
AU2020334196A1 (en) 2019-08-20 2022-03-03 Nuritas Limited Peptides for treating muscle atrophy
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
WO2021078912A1 (en) 2019-10-22 2021-04-29 Nuritas Limited Treatment of non-alcoholic fatty liver disease
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CA3182458A1 (en) 2020-06-24 2021-12-30 Laura ROSEN Engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2022148412A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合cd47的抗体及其抗原结合片段
WO2022148414A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合pd-l1的抗体及其抗原结合片段
US20250277044A1 (en) 2021-01-08 2025-09-04 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
TW202245838A (zh) 2021-01-26 2022-12-01 美商維爾生物科技股份有限公司 用於治療b型肝炎病毒感染的組成物及方法
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
BR112023019512A2 (pt) 2021-03-26 2023-10-31 Abcuro Inc Anticorpos anti-klrg1
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
EP4322984A1 (en) 2021-04-14 2024-02-21 University College Cork-National University of Ireland Cork Psg1 for use in the treatment of osteoarthritis
WO2022219008A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
JP2024528877A (ja) 2021-07-26 2024-08-01 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN117586388A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 改进的β淀粉样蛋白寡聚体特异性结合抗体
CN117589996A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
JP2025534040A (ja) 2022-10-14 2025-10-09 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 腱傷害の治療における使用のための胎盤発現タンパク質
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222080A1 (en) * 1973-03-22 1974-10-18 Viejo Jacques Stabilisation of pepsin - by salt formation with a carboxy polymethylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5623587A (en) * 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
SU1022988A1 (ru) * 1979-09-28 1983-06-15 Всесоюзный кардиологический научный центр АМН СССР Стабилизированна урокиназа,обладающа тромболитической активностью,и способ ее получени

Also Published As

Publication number Publication date
BR8206347A (pt) 1983-09-27
US4495285B1 (OSRAM) 1986-09-23
JPH0525470B2 (OSRAM) 1993-04-13
GB2110219B (en) 1985-01-09
SE8206173L (sv) 1983-05-01
GB2110219A (en) 1983-06-15
DE3240174C2 (OSRAM) 1990-08-23
SE8206173D0 (sv) 1982-10-29
CH658669A5 (fr) 1986-11-28
CA1203764A (en) 1986-04-29
FR2515684A1 (fr) 1983-05-06
US4495285A (en) 1985-01-22
DE3240174A1 (de) 1983-05-19
JPS5896026A (ja) 1983-06-07
FR2515684B1 (fr) 1986-04-04

Similar Documents

Publication Publication Date Title
SE457800B (sv) Plasminogenaktivatorderivat
US4640835A (en) Plasminogen activator derivatives
WO1998016503A3 (en) The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HU185223B (en) Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen
JPH0231952B2 (OSRAM)
EP0155388B1 (en) Enzyme-protein conjugate, process for its preparation and pharmaceutical use thereof
US5646127A (en) Treatment of cardiac ischemia by administration of a fraction of partially depolymerized DNA
RU2095081C1 (ru) Фармацевтическая композиция антивирусного действия
US4507283A (en) Pharmacologically active compounds
NZ229402A (en) Hirudin derivative bound to a soluble carrier
EP0151593A1 (en) ENZYMATIC DERIVATIVES.
RU2220982C9 (ru) Аргакрил - новое антисептическое и гемостатическое средство
CA1283047C (en) Stabilized plasminogen activator precursor and method of producing the same
EP0419252B1 (en) Thrombolytic composition containing tissue type plasminogen activator or derivative thereof
JPS6360938A (ja) 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
JPH01240186A (ja) フィブリン特異性２本鎖プラスミノーゲンアクチベーター
RU2247777C2 (ru) Модифицированный активатор плазминогена урокиназного типа, последовательность днк, рекомбинантная плазмида, штамм-продуцент, способ получения модифицированного активатора плазминогена урокиназного типа и фармацевтическая композиция, обладающая тромболитическим действием
Hostetter The third component of complement: new functions for an old friend
JPH0569508B2 (OSRAM)
IT8268274A1 (it) Nuovi derivati di attivatori di plasminogeno procedimento per la loro preparazione ed agente trombolitico comprendente tali derivati
JPS59167520A (ja) 新規プラスミノ−ゲンアクチベ−タ誘導体およびその製造法ならびにそれを含有する医薬品
JPS59204130A (ja) 新規プラスミノ−ゲンアクチベ−タ誘導体を含有してなる経口投与薬剤
SU948114A1 (ru) Олигомер урокиназы,обладающий фибринолитическим действием,и способ его получени
JPH02193984A (ja) 水溶性２―アミノフェノキサジン―３―オンおよびその誘導体の製造方法
Prosser et al. Circular dichroism spectroscopic studies of native and turnover-modified sulfatase A

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8206173-0

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8206173-0

Format of ref document f/p: F